SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System

Phase 3

Completed

• Conditions: Coronary Artery Disease; Everolimus; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis
• Interventions: Device: Coronary artery drug eluting stent placement; Device: Coronary artery stent placement

• Registration Number: NCT00180453
• Lead Sponsor: Abbott Medical Devices

Brief Summary

Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial.

Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK VISION® metallic stent(stent length: 18mm, diameter: 3.0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180 days and 1 year

Detailed Description

The SPIRIT FIRST clinical trial will enroll approximately 60 patients and will assess the feasibility and performance of the XIENCE V® Everolimus Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions. In this trial, the XIENCE V® Everolimus Eluting Coronary Stent System will be compared to the MULTI-LINK VISION® metallic stent which is CE marked and FDA approved and is available for commercial use in Europe and in the United States. The SPIRIT FIRST Clinical trial will enroll approximately 60 patients (30 patients in the test arm and 30 patients in the control arm) with de novo native coronary artery lesions in 4 clinical sites in The Netherlands and Germany

Study Timeline

• Study Start: 2003-12
• Primary Completion: 2005-04
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Status Verified: 2009-06
• Study Completion: 2009-06
• Last Update Submitted: 2010-01-05
• Last Update Posted: 2010-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Angiographic

1. Planned single, de novo, type A - B1, native coronary artery lesion treatment.
2. Target lesion must be located in a native vessel with a diameter of 3.0 mm assessed by QCA on-line.
3. Target lesion length ≤ 12 mm, assessed by QCA on-line.
4. The target lesion must be in a major artery or branch with a stenosis of ≥ 50% and < 100% assessed by QCA on-line and with a TIMI flow of ≥ 1.

Exclusion Criteria

1. Patient has had a known acute myocardial infarction (greater than two times the upper limit of normal CK with presence of CK-MB) within 3 days preceding the index procedure and CK has not returned to normal limits at the time of the procedure.
2. Patient has current or a history of unstable arrhythmias, regardless of whether cardiac rhythm management devices are used (e.g., pacemaker, Automatic Implantable Cardioverter Defibrillator).
3. Patient has a known left ventricular ejection fraction ≥ 30%.
4. Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant.
5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure.
6. Patient is receiving immunosuppression therapy or has known immunosuppressive disease.
7. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).
8. Patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, cobalt, chromium, nickel, tungsten, everolimus, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
9. Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).
10. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, patient on dialysis).
11. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
12. Patient has had a cerebrovascular accident (CVA) or stroke or transient ischemic neurological attack (TIA) within the past six months.
13. Patient has had a significant GI or urinary bleed within the past six months.
14. Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion or extreme anticoagulation.
15. Patient has other medical illness (e.g., cancer or congestive heart failure) or recent history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
16. Patient is already participating in another investigational use device or drug study or has completed the follow-up phase of another trial within the last 30 days.
17. Patient has received a drug eluting stent within the last 1 year.

Exclusion Criteria

Angiographic

1. The target lesion meets any of the following criteria:

   1. Aorto-ostial location
   2. Unprotected left main location
   3. Located within 2 mm of the origin of the LAD or LCX
   4. Located within or distal to an arterial or saphenous vein graft
   5. Located within 2 mm of a bifurcation
   6. Located distal to a previously implanted stent (same major epicardial vessel)
   7. Located in a major epicardial vessel that has been previously treated with brachytherapy
   8. Located in a major epicardial vessel that has been previously treated with any type of PCI (e.g., POBA, stent, cutting balloon, atherectomy), except if previous treatment occurred in a side branch distal to target lesion at least 180 days preceding the index procedure
   9. Involves jailing of side branches > 2.0 mm in diameter
   10. Total occlusion (TIMI flow 0)
   11. Excessive tortuosity proximal to or within the lesion
   12. Extreme angulation (≥ 90%) proximal to or within the lesion
   13. Moderate to heavy calcification
   14. Restenotic from previous intervention

2. The target vessel contains thrombus.

3. Another significant lesion (≥ 40 %DS) is located in the same major epicardial vessel as the target lesion.

4. Patient has a high probability that a procedure other than pre-dilatation and stenting will be required for treatment of the target vessel (e.g. atherectomy, cutting balloon).

5. Patient has additional lesion(s) for which an intervention within 180 days (prior to or after) of the index procedure would be required or has been performed.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Coronary artery drug eluting stent placement	Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
2	Coronary artery stent placement	Abbott Vascular MULTI-LINK VISION® BMS

Primary Outcome Measures

Name	Time	Method
In-stent late loss	at 180 days post procedure

Secondary Outcome Measures

Name	Time	Method
In-stent late loss	at 1 year post procedure
In-segment Late Loss	at 180 days and 1 year
In-stent and in-segment %Volume Obstruction	at 180 days and 1 year
In-stent and in-segment %Diameter Stenosis	at 180 days and 1 year
In-stent and in-segment Angiographic Binary Restenosis rate	at 180 days and 1 year
Persisting incomplete apposition, late incomplete apposition, aneurysm, thrombus, persisting dissection	at 180 days and 1 year
Major Adverse Cardiac Events	at 30, 180, 270 days, and 1, 2, 3, 4, 5 years
Target Vessel Failure	at 30, 180, 270 days, and 1, 2, 3, 4, 5 years
Acute success (device, procedure and clinical)	Acute

Trial Locations

Locations (7)

Academisch Medisch Centrum; 🇳🇱 Amsterdam, Netherlands

Skejby Sygehus; 🇩🇰 Aarhus, Denmark

Herzzentrum Bad Oeynhausen; 🇩🇪 Bad Oeynhausen, Germany

Herzzentrum Bad Krozingen; 🇩🇪 Bad Krozingen, Germany

Kerckhoff-Klinik; 🇩🇪 Bad Nauheim, Germany

Herzzentrum Siegburg GmbH; 🇩🇪 Siegburg, Germany

Erasmus Medical Center; 🇳🇱 Rotterdam, Netherlands